[In vivo antibacterial activity of cefbuperazone. Synergy of cefbuperazone for bactericidal effect with human polymorphonuclear leukocytes].
Studies were done utilizing E. coli No. 59 which are resistant against human and mouse serum, and the following results were obtained. The therapeutic effect of cefbuperazone (CPBZ) against systemic infections of mice was much higher than that of cefmetazole (CMZ), cefotetan (CTT), latamoxef (LMOX) and cefoperazone (CPZ). Synergistic bactericidal effect with human polymorphonuclear leukocytes was more marked for CBPZ than CMZ.
D000818:Animals; D001770:Blood Bactericidal Activity; D015311:Cefmetazole; D002438:Cefoperazone / Q000627:therapeutic use; D015313:Cefotetan; D002513:Cephamycins / Q000627:therapeutic use*; D004926:Escherichia coli / Q000187:drug effects; D004927:Escherichia coli Infections / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009070:Moxalactam / Q000627:therapeutic use; D009504:Neutrophils / Q000276:immunology*
D002513:Cephamycins; D015311:Cefmetazole; D015313:Cefotetan; D002438:Cefoperazone; C035978:cefbuperazone; D009070:Moxalactam